Long-term remission by brentuximab vedotin for non-mediastinal gray zone lymphoma refractory to autologous stem cell transplantation

Treatment for B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma, especially in relapsed or refractory case, is not established. A 35-year-old Japanese woman with this type of lymphoma relapsed after ABVD chemotherapy received salvage chemotherapies. Even after hidh-dose chemotherapy followed by autologous stem cell transplantation, only partial response could be achieved. Consolidative involved-field radiation therapy did not induce complete response and four months later a new lesion appeared at the skin inside the irradiated field.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research

Related Links:

Publication date: Available online 30 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kazutoshi Ebisawa, Yosuke Masamoto, Junji Koya, Arika Shimura, Aya Shinozaki-Ushiku, Kazuhiro Toyama, Kumi Nakazaki, Mineo KurokawaAbstractTreatment for B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma, especially in relapsed or refractory case, is not established. A 35-year-old Japanese woman with this type of lymphoma relapsed after ABVD chemotherapy received salvage chemotherapies. Even after hidh-dose chemotherapy followed by autologous s...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Discussion In this section, we discuss the mechanisms responsible for lymphomagenesis in the various inborn errors of immunity and provide an overview of the treatment. Defects in Immune Responses That Predispose to Lymphomagenesis in PIDDs The complex immune mechanisms and their interplay that predisposes to neoplastic transformation of B or T cells and development of lymphomas in PIDD patients has not been fully elucidated. However, it is expected that the etiology in most cases is multifactorial and related to a dynamic regulation of immune response and environmental triggers (Figure 3). An underlying intrinsic susce...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Discussion Suppressor of cytokine signaling 1 is an essential molecule for maintaining immune homeostasis and subverting inflammation. Disorders arising from excess inflammation or SOCS1 deficiency can be potentially treated with SOCS1 mimetics (Ahmed et al., 2015). While SOCS1 has promising potential in many disorders, it should be noted that new targets and actions of SOCS1 are still being discovered and not all the effects of this protein are beneficial in autoimmune diseases and cancer. For instance, SOCS1 degrades IRS1 and IRS2, required for insulin signaling, via the SOCS Box domain, thus, limiting its potential in ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
ConclusionThis review provides estimates for response and survival to aid in decision making when considering ASCT for patients with PCNSL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionMesenteric involvement of DLBCL can be successfully targeted with localized ISRT fields using IMRT and daily CT-image guidance.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Treatment-induced oral mucositis (OM) is a pathological process characterized by mucosal damage, from mild inflammation to deep ulcerations and affecting one or more parts of the gastrointestinal tract as a consequence of chemotherapy and radiation therapy. The major complications in haematological malignancies patients (pts) submitted to HSCT are infections, in particular due to E.Coli, P. Aeruginosa and Candida. Treatment of OM is only palliative. Several studies showed the successful treatment of the symptoms associated to OM with the strain of Lactobacillus brevis, due to the process of microflora manipulation.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
We present the case of a 61-year-old female patient 47 days after autologous stem cell transplant for MM who developed cardiac tamponade owing to extramedullary recurrence of myeloma, pulmonary embolism, and takotsubo cardiomyopathy. We performed a review of the published studies of all cases of MM presenting at diagnosis or relapse with cardiac or pericardial involvement in the past 25 years. Including our patient, 34 patients with plasmacytoma involving cardiac or pericardial structures were identified from the literature search. Approximately equal numbers of patients were male and female (42% and 57%, respectively). Th...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We present the case of a 61-year-old female patient 47 days after autologous stem cell transplant for MM who developed cardiac tamponade owing to extramedullary recurrence of myeloma, pulmonary embolism, and takotsubo cardiomyopathy. We performed a review of the published studies of all cases of MM presenting at diagnosis or relapse with cardiac or pericardial involvement in the past 25 years. Including our patient, 34 patients with plasmacytoma involving cardiac or pericardial structures were identified from the literature search. Approximately equal numbers of patients were male and female (42% and 57%, respectively). Th...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion The reporting of all cases to date focused on reporting unusual findings, rather than treatment approaches or new therapeutic strategies which may benefit patients. We suggest a database be formed of all cases of cardiac and pericardial EMPs with a focus on predictive disease variables, standardized staging, outcome and survival to ensure patients are optimally treated in the modern era.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Chronic Myelomonocytic Leukemia;   Hodgkin Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Malignant Neoplasm;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chemotherapy | Hematology | Japan Health | Leukemia | Lymphoma | Myeloma | Radiation Therapy | Skin | Stem Cell Therapy | Stem Cells | Transplants